Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romosozumab for Myeloma-related Osteolytic Disease in Postmenopausal Women With Multiple Myeloma and Osteoporosis
NCT05775094Phase 1Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Mar 2023
- Primary completion
- Mar 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of romosozumab in osteoporosis and multiple myeloma (MM), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Percent change in bone formation marker, P1NP up to 2 years. Started Mar 2023; status: active, not recruiting.
02
Drugs
romosozumab
03
Conditions
osteoporosismultiple myeloma (MM)
Beyond the preview
Go deeper on NCT05775094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05775094.